---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-001519"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:43:03.343617+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Homology Medicines receives Nasdaq bid price deficiency notice; compliance deadline June 26, 2024

## Summary
- Received Nasdaq deficiency notice on Dec 29, 2023 for bid price below $1.00 for 30 consecutive business days.
- Has 180 calendar days, until June 26, 2024, to regain compliance by closing at $1.00+ for 10 consecutive business days.
- Plans to seek stockholder approval for reverse stock split in connection with proposed merger with Q32 Bio.
- If not compliant by June 26, may qualify for second 180-day period by transferring to Nasdaq Capital Market.
- Failure could lead to delisting, subject to appeal; no assurance of success.

## SEC filing metadata
- accession: 0001193125-24-001519
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312524001519/0001193125-24-001519-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312524001519/d648217d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-001519
- JSON: https://secwatch.observer/filing/0001193125-24-001519.json
- Plain text: https://secwatch.observer/filing/0001193125-24-001519.txt

## Key facts
- Listing & Compliance Notices
  Q32 Bio Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: December 29, 2023, Homology Medicines, Inc. (the “ Company ” or “ Homology ”) received a letter (the “ Nasdaq Notification ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Price Requirement ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until June 26, 2
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312524001519/0001193125-24-001519-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.